Drugs / BI 765423
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06232252 | May 2024 → Apr 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05658107 | Jan 2023 → Mar 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07036523 | Nov 2025 → Mar 2027 expected | idiopathic pulmonary fibrosis | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 765423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05658107 ↗ |
| Route | Intravenous | “following intravenous administration of single rising doses” NCT05658107 ↗ |